Jonathan Slonin - Jun 6, 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role: Chief Clinical Officer
Signature: /s/ Kristen Williams, Attorney-in-Fact
Stock symbol: PCRX
Transactions as of: Jun 6, 2022
Transactions value $: -$22,217
Form type: 4
Date filed: 6/8/2022, 07:45 PM
Previous filing: May 25, 2022
Next filing: Jul 7, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCRX	Common Stock	Sale	-$22.2K	-362	-1.27%	$61.37	28.2K	Jun 6, 2022	Direct	F1
transaction	PCRX	Common Stock	Award	$0	+9.9K	+35.11%	$0.00	38.1K	Jun 8, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCRX	Stock Option (Right to Buy)	Sale	$0	+24.8K		$0.00	24.8K	Jun 8, 2022	Common Stock	24.8K	$59.39	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
F2	Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F3	The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.